“`html
Oxford University spin-out OrganOx, the innovative transplant technology firm, has been acquired by Japanese medical devices conglomerate Terumo in a $1.5 billion (£1.2 billion) transaction.
The purchase, one of the most substantial ever for a UK medical technology enterprise, highlights Britain’s prowess in scientific ingenuity but will also amplify discussions regarding the nation’s capability to maintain ownership of its most successful spin-outs.
OrganOx was established in 2008 by professors Constantin Coussios and Peter Friend, who invented revolutionary technology to sustain donor organs outside the human body for up to 24 hours prior to transplantation. The apparatus has since been employed in over 6,000 liver transplants globally.
Earlier this year, the company’s primary device received the esteemed MacRobert Award from the Royal Academy of Engineering, solidifying its status as one of Britain’s most important medical advancements of recent decades.
Both founders are minority stakeholders and are anticipated to secure substantial returns from the transaction. Other recipients include OrganOx personnel, Oxford University, the Royal County of Berkshire Pension Fund, and BGF – the venture capital firm supported by Barclays, HSBC, Lloyds, and NatWest – which is poised to gain its largest-ever yield, estimated at £175 million.
Professor Friend, a surgeon and specialist in transplantation, remarked that the agreement demonstrated how “British universities are adept at fostering innovation and then realizing successful commercialization.” Coussios, director of the Oxford Institute of Biomedical Engineering, referred to it as a “win-win scenario” for patients, healthcare providers, and investors.
Oxford University praised the agreement as the largest-ever acquisition of one of its spin-outs.
Despite its financial success, the transaction is likely to prompt renewed worries regarding the future of UK innovation ventures. OrganOx’s transfer to a foreign owner follows a trend of British technology companies being purchased before achieving full maturity or deciding to list on the London Stock Exchange.
Critics contend that ongoing foreign acquisitions threaten to undermine Britain’s scientific and technological foundation, with long-term advantages frequently being directed overseas instead of supporting domestic growth.
Terumo, headquartered in Tokyo, indicated that OrganOx would become a wholly owned subsidiary and that the agreement would hasten its entry into the organ transplantation arena. The corporation stated it aimed to broaden access to OrganOx’s life-saving technology on an international scale.
For investors and researchers, the sale of OrganOx marks a pivotal moment. For policymakers, however, it may act as yet another reminder of the difficulties Britain confronts in converting scientific excellence into sustained industrial progress.
With one of Oxford’s most lauded spin-outs now in Japanese hands, the transaction underscores both the world-class innovation generated by British universities – and the ongoing question of how to retain more of that success domestically.
Source link
“`
